CGC
Canopy Growth Corporation
CGC has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CGC overall, supported by stronger fundamentals.
CGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
CGC's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CGC PE Valuation
CGC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CGC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$1.38 |
| Q2 2026 | -$0.47 | +$2.47 |
| Q1 2026 | -$0.60 | +$3.31 |
| Q4 2025 | -$1.25 | +$2.52 |
| Q3 2025 | -$1.91 | +$2.92 |
| Q2 2025 | -$2.94 | +$3.87 |
| Q1 2025 | -$3.91 | +$2.27 |
| Q4 2024 | -$3.77 | +$6.37 |
CGC is still losing money, but far less than before: $0.53 per share over the past year, against $53.01 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CGC on earnings quality, reporting a profit while its opponent remains loss making.
CGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $57.2M | +22% |
| Q2 2026 | $57.1M | +13% |
| Q1 2026 | $50.1M | +9.6% |
| Q4 2025 | $52.4M | -0.3% |
| Q3 2025 | $46.9M | +5.9% |
| Q2 2025 | $50.7M | +8.9% |
| Q1 2025 | $45.7M | -11% |
| Q4 2024 | $52.6M | -4.8% |
CGC's revenue is recovering but still below its 2020 peak: $57M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | -2.9 points |
| Q2 2026 | -27% | +4.1 points |
| Q1 2026 | -134% | -106 points |
| Q4 2025 | -35% | -3.5 points |
| Q3 2025 | -25% | +48 points |
| Q2 2025 | -31% | +13 points |
| Q1 2025 | -28% | +119 points |
| Q4 2024 | -32% | +45 points |
CGC's operating margin was −28% last quarter, down 2.9 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CGC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CGC on profitability, with a higher operating margin.
CGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.9M | +$2.6M |
| Q2 2026 | -$18.1M | -$9.9M |
| Q1 2026 | -$13.5M | +$11.9M |
| Q4 2025 | -$13.4M | +$6.4M |
| Q3 2025 | -$13.5M | +$26.2M |
| Q2 2025 | -$8.2M | +$31M |
| Q1 2025 | -$25.5M | -$9.8M |
| Q4 2024 | -$19.8M | +$3.5M |
CGC has burned cash in almost every quarter: −$56M over the past year, against −$67M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CGC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +846K shares |
| 1 year | +125% | +235M shares |
| 3 years | +770% | +374M shares |
| 5 years | +1035% | +386M shares |
CGC has 423M diluted shares, up 125% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CGC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CGC Net Leverage
CGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 6.6 | Oversold |
CGC's weekly RSI is 25 (oversold) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CGC PE vs Healthcare Sector
| Metric | CGC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CGC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.74 | 23% below |
| 20 week MA | $0.88 | 35% below |
| 50 week MA | $1.02 | 44% below |
| 100 week MA | $1.25 | 54% below |
| 200 week MA | $4.80 | 88% below |
CGC is in a downtrend: it's below all five of its weekly moving averages, and 88% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CGC on trend strength, trading above more of its moving averages.
CGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $192.1 | $258.6 | +35% |
| 2021 | $258.6 | $96.2 | -63% |
| 2022 | $96.2 | $23.3 | -76% |
| 2023 | $23.3 | $5.11 | -78% |
| 2024 | $5.11 | $2.78 | -46% |
| 2025 | $2.78 | $1.19 | -57% |
| 2026 YTD | $1.19 | $0.57 | -52% |
CGC has finished five years in a row lower, and it's down 52% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CGC on returns for 2026, with the stronger performance.